HIV Treatment Information for Adults
Get drug information for adult patients
Dosing is for adult patients ≥ 18 years unless noted otherwise
*Please refer to the most current drug label for adult patients with renal impairment
General Considerations:
Perform pregnancy testing before initiating an antiretroviral agent in adolescents and adults of childbearing potential
Filter by
| Brand | Generic | Drug Class | Dosage Form | Adult Dosing | Visit Drugs@FDA to view |
|---|---|---|---|---|---|
| Atripla* | efavirenz 600 mg emtricitabine 200 mg tenofovir disoproxil fumarate 300 mg |
Combination Products | Oral Tablet | One tablet once daily on an empty stomach, preferably at bedtime | Atripla Label |
| Biktarvy* | bictegravir 50 mg emtricitabine 200 mg tenofovir alafenamide 25 mg |
Combination Products | Oral Tablet | One tablet once daily with or without food | Biktarvy Label |
| Cimduo* | lamivudine 300 mg tenofovir disoproxil fumarate 300 mg |
Combination Products | Oral Tablet | One tablet once daily with or without food | Cimduo Label |
| Combivir* | zidovudine 300 mg lamivudine 150 mg |
Combination Products | Oral Tablet | One tablet twice daily | Combivir Label |
| Complera* | emtricitabine 200 mg rilpivirine 25 mg tenofovir disoproxil fumarate 300 mg |
Combination Products | Oral Tablet | One tablet once daily with food | Complera Label |
| Delstrigo* | doravirine 100 mg lamivudine 300 mg tenofovir disoproxil fumarate 300 mg |
Combination Products | Oral Tablet | One tablet once daily with or without food | Delstrigo Label |
| Descovy* | emtricitabine 200 mg tenofovir alafenamide 25 mg |
Combination Products | Oral Tablet | One tablet once daily with or without food | Descovy Label |
| Dovato* | dolutegravir 50 mg lamivudine 300 mg |
Combination Products | Oral Tablet | One tablet once daily with or without food | Dovato Label |
| Epzicom* | abacavir 600 mg lamivudine 300 mg |
Combination Products | Oral Tablet | One tablet once daily with or without food | Epzicom Label |
| Evotaz* | atazanavir 300 mg cobicistat 150 mg |
Combination Products | Oral Tablet | For treatment-naive and -experienced adults: One tablet once daily with food | Evotaz Label |
| Genvoya* | elvitegravir 150 mg cobicistat 150 mg tenofovir alafenamide 10 mg emtricitabine 200 mg |
Combination Products | Oral Tablet | One tablet once daily with food | Genvoya Label |
| Juluca | dolutegravir 50 mg rilpivirine 25 mg |
Combination Products | Oral Tablet | One tablet once daily with a meal | Juluca Label |
| Kaletra | lopinavir 100 mg and ritanovir 25 mg lopinavir 200 mg and ritonavir 50 mg |
Combination Products | Oral Tablet | Given once daily or twice daily regimen with or without food. Please see Full Prescribing Information for dosing regimen. | Kaletra Label |
| Kaletra | lopinavir 80 mg/mL and ritonavir 20 mg/mL | Combination Products | Oral Solution | Given once daily or twice daily regimen with food. Please see Full Prescribing Information for dosing regimen. | Kaletra Label |
| Odefsey* | emtricitabine 200 mg rilpivirine 25 mg tenofovir alafenamide 25 mg |
Combination Products | Oral Tablet | One tablet once daily with a meal | Odefsey Label |
| Prezcobix* | darunavir 800 mg cobicistat 150 mg |
Combination Products | Oral Tablet | For treatment-naïve and treatment-experienced adults with no darunavir resistance associated substitutions: one tablet once daily with food | Prezcobix Label |
| Stribild* | elvitegravir 150 mg cobicistat 150 mg emtricitabine 200 mg tenofovir disoproxil fumarate 300 mg |
Combination Products | Oral Tablet | One tablet once daily with food | Stribild Label |
| Symfi* | efavirenz 600 mg lamivudine 300 mg tenofovir disoproxil fumarate 300 mg |
Combination Products | Oral Tablet | One tablet once daily on an empty stomach, preferably at bedtime | Symfi Label |
| Symfi Lo* | efavirenz 400 mg lamivudine 300 mg tenofovir disoproxil fumarate 300 mg |
Combination Products | Oral Tablet | One tablet once daily on an empty stomach, preferably at bedtime | Symfi Lo Label |
| Symtuza* | darunavir 800 mg cobicistat 150 mg emtricitabine 200 mg tenofovir alafenamide 10 mg |
Combination Products | Oral Tablet | One tablet once daily with food | Symtuza Label |
| Triumeq* | dolutegravir 50 mg abacavir 600 mg lamivudine 300 mg |
Combination Products | Oral Tablet | One tablet once daily with or without food | Triumeq Label |
| Trizivir* | abacavir 300 mg lamivudine 150 mg zidovudine 300 mg |
Combination Products | Oral Tablet | One tablet twice daily with or without food | Trizivir Label |
| Truvada* | emtricitabine (FTC), tenofovir disoproxil fumarate (TDF): 100 mg FTC/150 mg TDF 133 mg FTC/200 mg TDF 167 mt FTC/250 mg TDF 200 FTC/300 mg TDF |
Combination Products | Oral Tablet | One tablet once daily with or without food | Truvada Label |
| Emtriva* | emtricitabine 200 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Capsule | One capsule once daily with or without food | Emtriva Label |
| Emtriva* | emtricitabine 10 mg/mL | Nucleoside Reverse Transcriptase Inhibitors | Oral Solution | 240 mg (24 mL) once daily with or without food | Emtriva Label |
| Epivir* | lamivudine 150 mg, 300 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Tablet | 150 mg tablet twice daily or 300 mg tablet once daily with or without food | Epivir Label |
| Epivir* | lamivudine 10 mg/mL | Nucleoside Reverse Transcriptase Inhibitors | Oral Solution | 30 mL (300 mg) daily max with or without food | Epivir Label |
| Retrovir* | zidovudine 100 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Capsule | 300 mg twice daily | Retrovir Label |
| Retrovir* | zidovudine 10 mg/mL | Nucleoside Reverse Transcriptase Inhibitors | Oral Syrup | 30mL (300 mg) twice daily | Retrovir Label |
| Retrovir* | zidovudine 20-ml single-use vial (10 mg/mL) | Nucleoside Reverse Transcriptase Inhibitors | Intravenous Injection | Recommended dose: 1 mg/kg infused at a constant rate over 1 hour every 4 hours | Retrovir Label |
| Temixys* | lamivudine 300 mg tenofovir disoproxil fumarate 300 mg |
Nucleoside Reverse Transcriptase Inhibitors | Oral Tablet | One tablet once daily with or without food | Temixys Label |
| Videx* | didanosine 2 g, 4 g | Nucleoside Reverse Transcriptase Inhibitors | Oral Powder for Solution | Dosing is based on body weight and administered on an empty stomach at least 30 minutes before or 2 hours after eating. Please see Full Prescribing Information for dosing. | Videx Label |
| Videx EC* | didanosine delayed-release capsule 125 mg, 200 mg, 250 mg, 400 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Capsule | Dosing is based on body weight and administered on an empty stomach once daily. Please see Full Prescribing Information for details | Videx EC Label |
| Viread* | tenofovir disoproxil fumarate 150 mg, 200 mg, 250 mg, 300 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Tablet | • For patients weighing at least 35 kg, one tablet (300 mg) taken orally once daily without regard to food • For patients weighing at least 17 kg who can swallow an intact tablet, one tablet (150 mg, 200 mg, 250 mg, or 300 mg based on body weight) once daily taken orally without regard to food. Please see Full Prescribing Information for details |
Viread Label |
| Viread* | tenofovir disoproxil fumarate 40 mg per gram of powder | Nucleoside Reverse Transcriptase Inhibitors | Oral Powder | 8 mg per kg oral powder (up to a maximum of 300 mg) taken once daily with soft food | Viread Label |
| Zerit* | stavudine 15 mg, 20 mg, 30 mg, 40 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Capsule | •For patients weighing less than 60 kg: 30 mg every 12 hours •For patients weighing at least 60 kg: 40 mg every 12 hours |
Zerit Label |
| Ziagen | abacavir 300 mg | Nucleoside Reverse Transcriptase Inhibitors | Oral Tablet | • Administered as either 300 mg twice daily or 600 mg once daily | Ziagen Label |
| Ziagen | abacavir 20 mg/mL | Nucleoside Reverse Transcriptase Inhibitors | Oral Solution | • Administered as either 15 mL (300 mg) twice daily or 30 mL (600 mg) once daily • For patients with mild hepatic impairment (Child-Pugh A): 10 mL twice daily. Ziagen is contraindicated in patients with moderate to severe hepatic impairment |
Ziagen Label |
| Edurant | rilpivirine 25 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Tablet | One tablet once daily with a meal | Edurant Label |
| Intelence | etravirine 25 mg, 100 mg, 200 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Tablet | 200 mg (one 200-mg tablet or two 100-mg tablet) twice daily following a meal | Intelence Label |
| Pifeltro | doravirine 100 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Tablet | One tablet once daily with or without food | Pifeltro Label |
| Rescriptor | delavirdine 200 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Tablet | 400 mg (four 100-mg tablets, or two 200-mg tablets as intact tablets) three times daily for patients with or without food | Rescriptor Label |
| Sustiva | efavirenz 600 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Tablet | 600 mg once daily on an empty stomach, preferably at bedtime. Please see the Full Prescribing Information for dosage adjustment if taken with other medications. | Sustiva Label |
| Sustiva | efavirenz 50 mg, 200 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Capsule | 600 mg once daily on an empty stomach, preferably at bedtime. Please see the Full Prescribing Information for dosage adjustment if taken with other medications. | Sustiva Label |
| Viramune* | nevirapine 200 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Tablet | 200 mg once daily for 14 days followed by 200 mg twice daily | Viramune Label |
| Viramune* | nevirapine 50 mg/5 mL | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Suspension | 20 mL once daily for 14 days followed by 20 mL twice daily | Viramune Label |
| Viramune XR* | nevirapine extended-release 400 mg | Nonnucleoside Reverse Transcriptase Inhibitors | Oral Tablet | Must initiate therapy with one 200 mg tablet of immediate-release VIRAMUME once daily for the first 14 days, followed by one 400 mg tablet of VIRAMUNE XR daily. Patients already on the immediate-release VIRAMUNE twice daily can be switched to VIRAMUNE XR 400 mg once daily without the 14-day lead-in period of immediate-release VIRAMUNE. Please see Full Prescribing Information for dosing details |
Viramune XR Label |
| Aptivus | tipranavir 250 mg | Protease Inhibitors | Oral Capsule | 500 mg (two 250 mg capsules) co-administered with 200 mg of ritonavir, twice daily can be taken with or without meals | Aptivus Label |
| Aptivus | tipranavir 100 mg/mL | Protease Inhibitors | Oral Solution | 5 mL oral solution co-administered with 200 mg of ritonavir, twice daily can be taken with or without meals | Aptivus Label |
| Crixivan | indinavir 200 mg, 400 mg | Protease Inhibitors | Oral Capsule | 800 mg (usually two 400-mg capsules) every 8 hours without food but with water 1 hour before or 2 hours after a meal | Crixivan Label |
| Invirase | saquinavir mesylate 500 mg | Protease Inhibitors | Oral Tablet | • 1000 mg in combination with ritonavir 100 mg twice daily • Treatment-naïve patients initiating treatment with INVIRASE/ritonavir: First 7 days of treatment: INVIRASE 500 mg twice daily with ritonavir 100 mg twice daily. After 7 days: INVIRASE 1,000 mg twice daily with ritonavir 100 mg twice daily. •Please see Full Prescribing Information for dosing details for those switching from another regimen |
Invirase Label |
| Lexiva | fosamprenavir 700 mg | Protease Inhibitors | Oral Tablet | Dosing based on combination with ritonavir. Take tablets with or without food. Please see Full Pescribing Information for dosing details. | Lexiva Label |
| Lexiva | fosamprenavir 50 mg/mL | Protease Inhibitors | Oral Suspension | Dosing based on combination with ritonavir. Take oral suspension without food. Please see Full Pescribing Information for dosing details. | Lexiva Label |
| Norvir | ritonavir 100 mg | Protease Inhibitors | Oral Tablet | 600 mg twice daily to be taken with meals | Norvir Label |
| Norvir | ritonavir 100 mg/packet | Protease Inhibitors | Oral Powder | 600 mg twice daily to be taken with meals | Norvir Label |
| Norvir | ritonavir 80 mg/mL | Protease Inhibitors | Oral Solution | 7.5 mL (600 mg) twice daily to be taken with meals | Norvir Label |
| Prezista | darunavir 75 mg, 150 mg, 600 mg, 800 mg | Protease Inhibitors | Oral Tablet | • Treatment-naïve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 800 mg (one 800 mg tablet) taken with ritonavir 100 mg (one 100 mg tablet or capsule or 1.25 mL of a 80 mg per mL ritonavir oral solution) once daily and with food. • Treatment-experienced adult patients with at least one darunavir resistance associated substitution: 600 mg (one 600 mg tablet) taken with ritonavir 100 mg (one 100 mg tablet or capsule or 1.25 mL of a 80 mg per mL ritonavir oral solution) twice daily and with food. Please see Full Prescribing Information for dosing with oral solution. |
Prezista Label |
| Prezista | darunavir 100 mg/mL | Protease Inhibitors | Oral Suspension | • Treatment-naïve adult patients and treatment-experienced adult patients with no darunavir resistance associated substitutions: 8 mL (one 800 mg tablet) taken with ritonavir 100 mg ( 1.25 mL of a 80 mg per mL ritonavir oral solution) once daily and with food. • Treatment-experienced adult patients with at least one darunavir resistance associated substitution: 6 mL (one 600 mg tablet) taken with ritonavir 100 mg (1.25 mL of a 80 mg per mL ritonavir oral solution) twice daily and with food. Please see Full Prescribing Information for dosing with oral solution. |
Prezista Label |
| Reyataz* | atazanavir sulfate 150 mg, 200 mg, 300 mg | Protease Inhibitors | Oral Capsule | • Treatment-naive adults: 300 mg with ritonavir 100 mg once daily with food or 400 mg once daily with food. • Treatment-experienced adults: 300 mg with ritonavir 100 mg once daily with food. Please see Full Prescribing Information for dosing details for dosing with other antiretoriviral drugs and H2-receptor antagonists. |
Reyataz Label |
| Reyataz* | atazanavir sulfate 50 mg/packet | Protease Inhibitors | Oral Powder | • Treatment-naive adults: 300 mg with ritonavir 100 mg once daily with food or 400 mg once daily with food. •Treatment-experienced adults: 300 mg with ritonavir 100 mg once daily with food. REYATAZ oral powder must be mixed with food or beverage for administration and ritonavir must be given immediately afterwards. Please see Full Prescribing Information for dosing details for dosing with other antiretoriviral drugs and H2-receptor antagonists. |
Reyataz Label Information |
| Viracept | nelfinavir mesylate 250 mg, 625 mg | Protease Inhibitors | Oral Tablet | 1250 mg (five 250 mg tablets or two 625 mg tablets) twice daily or 750 mg (three 250 mg tablets) three times daily with a meal | Viracept Label |
| Fuzeon | enfuvirtide lyophilized powder 108 mg/vial | Fusion Inhibitors | Subcutaneous Injection | 90 mg (1 mL) twice daily injected subcutaneously into the upper arm, anterior thigh or abdomen | Fuzeon Label |
| Selzentry* | maraviroc 25 mg, 75 mg, 150 mg, 300 mg | Entry Inhibitors - CCR5 co-receptor antagonist | Oral Tablet | Dosing based on concomitant medications taken twice with or without food. Please see Full Prescribing for dosing recommendations. | Selzentry Label |
| Selzentry* | maraviroc 20 mg/mL | Entry Inhibitors - CCR5 co-receptor antagonist | Oral Solution | Dosing based on concomitant medications taken twice with or without food. Please see Full Prescribing for dosing recommendations. | Selzentry Label |
| Isentress | raltegravir film-coated 400 mg | Integrase Inhibitors | Oral Tablet | • Treatment-naïve patients or patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily: 1200 mg (2 x 600 mg) film-coated tablet orally, once daily or 400 mg film-coated tablet orally, twice daily. • Treatment experienced patients: 400 mg film-coated tablet orally, twice daily. • During coadministration with rifampin in adults, 800 mg (2 x 400 mg) twice daily. *Do not substitute ISENTRESS chewable tablets or ISENTRESS for oral suspension for the ISENTRESS 400 mg film-coated tablet or the ISENTRESS HD 600 mg film-coated tablet as the formulations have different pharmacokinetic profiles. |
Isentress Label |
| Isentress HD | raltegravir HD film-coated 600 mg | Integrase Inhibitors | Oral Tablet |
|
Isentress Label Information |
| Isentress | raltegravir 25 mg, 100 mg | Integrase Inhibitors | Oral Chewable Tablet | May be chewed or swallowed whole. Maximum daily dose is 300 mg taken by mouth twice daily | Isentress Label |
| Isentress | raltegravir 100 mg/packet | Integrase Inhibitors | Oral Suspension | Maximum daily dose is 100 mg taken by mouth twice daily | Isentress Label |
| Tivicay* | dolutegravir 10 mg, 25 mg, 50 mg | Integrase Inhibitors | Oral Tablet | 50 mg once to two times daily depending on treatment experience with or without food. Please see Full Prescribing Information for dosing details. | Tivicay Label |
|
Trogarzo |
ibalizumab-uiyk 150mg/ml |
CD4-directed post-attachment HIV-1 inhibitor |
Intravenous Injection |
Administered intravenously (IV) as a single loading dose of 2,000 mg (10 vials) followed by a maintenance dose of 800 mg (4 vials) every 2 weeks after dilution in 250 mL of 0.9% Sodium Chloride Injection, USP |
|
| Tybost* | cobicistat 150 mg | CYP3A Inhibitor | Oral Tablet | Must be in combination with atazanavir or darunavir at the same time, with food, and in combination with other HIV-1 antiretroviral agents. • 150 mg orally once daily with atazanavir 300 mg orally once daily for treatment-naive or treatment-experienced. • 150 mg orally once daily with darunavir 800 mg orally once daily in treatment-naive or treatment-experienced patients with no darunavir resistance-associated substitutions. Please see Full Prescribing Information for dosing details. |
Tybost Label |